Trusted Market and Commodities-Trade Intelligence
On 14 May 2019, Lier Chemical Co., Ltd. (Lier Chemical) announced that the fully owned subsidiary Guang’an Lier Chemical Co., Ltd. (Guang’an Lier) restored the trial production of the 1,000 t/a flumioxazin production line and related facilities. This was approved by the Safety Supervision Bureau of Guang’an City which sent experts for on-site inspection. It is in November 2018 that a safety accident happened to Guang’an Lier and the company made full rectification.
“We will make strict supervision of Guang’an Lier. We will urge it to strengthen the daily safety management, follow the governmental instructions for safe production, and check and screen out all potential risks for treatment. All this will guarantee the safe production,” said Lier Chemical.
On 15 October 2018, Lier Chemical disclosed that the 1,000 t/a flumioxazin production line and related facilities constructed in Guang’an Lier were put into regular operation. However, the safety accident then caused the production suspension. On 5 January 2019, Lier Chemical again unveiled that Guang’an Lier resumed the trial operation of the line after the complete rectification which was confirmed by the Branch of Economic & Technological Development Zone, the Safety Supervision Bureau of Guang’an City.
Four months later on 13 May, Lier Chemical again announced that Guang’an Lier’s 1,000 t/a flumioxazin production line and related facilities restarted trial operation.